Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy

Gregory B. Lim

DOI: https://doi.org/10.1038/s41569-024-01086-y

IF: 49.421

2024-09-20

Nature Reviews Cardiology

Abstract:Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Marianna Fontana,John L Berk,Julian D Gillmore,Ronald M Witteles,Martha Grogan,Brian Drachman,Thibaud Damy,Pablo Garcia-Pavia,Jorg Taubel,Scott D Solomon,Farooq H Sheikh,Nobuhiro Tahara,José González-Costello,Kenichi Tsujita,Caroline Morbach,Zoltán Pozsonyi,Mark C Petrie,Diego Delgado,Peter Van der Meer,Andrew Jabbour,Antoine Bondue,Darae Kim,Olga Azevedo,Steen Hvitfeldt Poulsen,Ali Yilmaz,Ewa A Jankowska,Vincent Algalarrondo,Andrew Slugg,Pushkal P Garg,Katherine L Boyle,Elena Yureneva,Nancy Silliman,Lilli Yang,Jihong Chen,Satish A Eraly,John Vest,Mathew S Maurer,HELIOS-B Trial Investigators

DOI: https://doi.org/10.1056/NEJMoa2409134

2024-08-30

Abstract:Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. Methods: In this double-blind, randomized trial, we assigned patients with ATTR-CM in a 1:1 ratio to receive vutrisiran (25 mg) or placebo every 12 weeks for up to 36 months. The primary end point was a composite of death from any cause and recurrent cardiovascular events. Secondary end points included death from any cause, the change from baseline in the distance covered on the 6-minute walk test, and the change from baseline in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score. The efficacy end points were assessed in the overall population and in the monotherapy population (the patients who were not receiving tafamidis at baseline) and were tested hierarchically. Results: A total of 655 patients underwent randomization; 326 were assigned to receive vutrisiran and 329 to receive placebo. Vutrisiran treatment led to a lower risk of death from any cause and recurrent cardiovascular events than placebo (hazard ratio in the overall population, 0.72; 95% confidence interval [CI], 0.56 to 0.93; P = 0.01; hazard ratio in the monotherapy population, 0.67; 95% CI, 0.49 to 0.93; P = 0.02) and a lower risk of death from any cause through 42 months (hazard ratio, 0.65; 95% CI, 0.46 to 0.90; P = 0.01). A primary end-point event occurred in 163 patients in the vutrisiran group and in 202 in the placebo group. In the overall population, treatment with vutrisiran resulted in less of a decline in the distance covered on the 6-minute walk test than placebo (least-squares mean difference, 26.5 m; 95% CI, 13.4 to 39.6; P<0.001) and less of a decline in the KCCQ-OS score (least-squares mean difference, 5.8 points; 95% CI, 2.4 to 9.2; P<0.001). Similar benefits were observed in the monotherapy population. The incidence of adverse events was similar in the two groups (99% in the vutrisiran group and 98% in the placebo group); serious adverse events occurred in 62% of the patients in the vutrisiran group and in 67% of those in the placebo group. Conclusions: Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B ClinicalTrials.gov number, NCT04153149.).
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy

Pablo Garcia‐Pavia,Martha Grogan,Parag Kale,John L. Berk,Mathew S. Maurer,Isabel Conceição,Marcelo Di Carli,Scott D. Solomon,Chongshu Chen,Elena Yureneva,John Vest,Julian D. Gillmore

DOI: https://doi.org/10.1002/ejhf.3138

2024-02-08

European Journal of Heart Failure

Abstract:Vutrisiran demonstrated beneficial effects on N‐terminal prohormone of brain‐type natriuretic peptide (NT‐proBNP) and other prespecified exploratory echocardiographic parameters versus external placebo in both a modified intent‐to‐treat (mITT) population and a cardiac subpopulation at Month 18. In a planned cohort undergoing 99mTc scintigraphy assessments, a majority of vutrisiran‐treated patients experienced reduced or stabilized radiotracer uptake versus baseline. Vutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy, and an acceptable safety profile, including no cardiac safety concerns. CI, confidence interval; LV, left ventricular; Q3M, every 3 months; SC, subcutaneous. aIn a planned cohort. AimsHELIOS‐A was a Phase 3, open‐label study of vutrisiran, an RNA interference therapeutic, in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy. This analysis evaluated vutrisiran's impact on exploratory cardiac endpoints in HELIOS‐A patients. Methods and resultsPatients were randomized 3:1 to subcutaneous vutrisiran 25 mg every 3 months or intravenous patisiran 0.3 mg/kg every 3 weeks (reference group) for 18 months. Exploratory cardiac endpoints included change from baseline in N‐terminal prohormone of brain‐type natriuretic peptide (NT‐proBNP) and echocardiographic parameters versus external placebo (APOLLO study). The modified intent‐to‐treat (mITT) population comprised randomized patients receiving any study drug (n = 122). A cardiac subpopulation with evidence of cardiac amyloid involvement (n = 40) was prespecified. 99mTc scintigraphy exploratory assessments in a planned vutrisiran‐treated cohort at select sites were compared with baseline. At Month 18, vutrisiran demonstrated beneficial effects on NT‐proBNP versus external placebo in the mITT and cardiac subpopulations (adjusted geometric mean fold change ratio [95% confidence interval] 0.480 [0.383–0.600], p = 9.606 × 10−10 and 0.491 [0.337–0.716], p = 0.0004, respectively). Benefits or trends towards benefit in echocardiographic parameters versus external placebo were observed for both populations. In 99mTc scintigraphy assessments, 32/47 (68.1%) and 31/48 (64.6%) patients exhibited reduced normalized left ventricular total uptake and heart‐to‐contralateral lung ratio, respectively. Perugini grade was reduced or unchanged versus baseline in 55/57 (96.5%) evaluable patients. No increase in cardiac adverse events was observed with vutrisiran versus external placebo. ConclusionsVutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with ATTRv amyloidosis with polyneuropathy, with an acceptable safety profile.

cardiac & cardiovascular systems
Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis

Andrew A. Girard,Brett W. Sperry

DOI: https://doi.org/10.1007/s10741-024-10444-4

2024-10-02

Heart Failure Reviews

Abstract:This focused review will highlight the results of HELIOS-B, the first randomized outcomes trial evaluating a gene silencing treatment for transthyretin cardiac amyloidosis (ATTR-CM). In HELIOS-B, vutrisiran was tested against placebo and demonstrated a 28% reduction in the composite of all-cause mortality and recurrent cardiovascular events. Additionally, there were clinically significant benefits on the 6-min walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA class. Discontinuation rates and adverse events were similar between treatment and control arms, suggesting that vutrisiran is well tolerated. In this review, these promising results are explored and compared with other treatment trials in ATTR-CM.

cardiac & cardiovascular systems
Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Marianna Fontana,Mathew S. Maurer,Julian D. Gillmore,Shaun Bender,Emre Aldinc,Satish A. Eraly,Patrick Y. Jay,Scott D. Solomon

DOI: https://doi.org/10.1016/j.jacc.2024.11.015

IF: 24

2024-11-24

Journal of the American College of Cardiology

Abstract:BACKGROUND Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods are needed to monitor patients and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM. OBJECTIVES We aimed to assess the clinical and prognostic significance of and the effect of vutrisiran treatment on outpatient worsening HF in patients with ATTR-CM from the HELIOS-B trial. METHODS Associations between outpatient worsening HF and a composite of all-cause mortality and recurrent cardiovascular (CV) events (CV hospitalizations and urgent HF visits), all-cause mortality, and other disease progression-related endpoints were evaluated. The impact of vutrisiran over 36 months on outpatient worsening HF and an expanded composite of all-cause mortality, recurrent CV events, and outpatient worsening HF was also assessed. RESULTS Overall, 321 patients (49.1%) had ≥1 outpatient worsening HF, 245 (37.5%) had ≥1 CV event(s), and 120 (18.3%) died; 237 patients (36.2%) had no events. Patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 2.04-3.27) and all-cause mortality (HR: 2.45; 95% CI: 1.70-3.52), as well as a greater deterioration in 6-minute walk test distance and Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and a greater increase in N -terminal prohormone of B-type natriuretic peptide. In recurrent event analyses over the double-blind period, vutrisiran versus placebo reduced the rate of outpatient worsening HF (relative rate ratio: 0.66; 95% CI: 0.56-0.78). Vutrisiran also reduced the risk of the composite of all-cause mortality, CV events, and outpatient worsening HF versus placebo (HR: 0.69; 95% CI: 0.57-0.83). CONCLUSIONS Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, and was associated with increased mortality, and reduced by vutrisiran.

cardiac & cardiovascular systems
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Marco Luigetti,Dianna Quan,John L. Berk,Isabel Conceição,Yohei Misumi,Chi-Chao Chao,Shaun Bender,Emre Aldinc,John Vest,David Adams

DOI: https://doi.org/10.1007/s40120-024-00595-9

2024-03-23

Neurology and Therapy

Abstract:Hereditary transthyretin (ATTRv, v for variant) amyloidosis is a rare, progressive, fatal disease with multisystem manifestations, caused by pathogenic variants in the transthyretin ( TTR) gene. Vutrisiran, an RNA interference therapeutic that results in rapid TTR knockdown, improved neuropathy and quality of life (QOL) versus external placebo in patients with ATTRv amyloidosis with polyneuropathy in the phase 3 HELIOS-A study (NCT03759379). This post hoc analysis evaluates the impact of baseline neuropathy severity on response to vutrisiran treatment.

clinical neurology
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Bahru A. Habtemariam,Verena Karsten,Husain Attarwala,Varun Goel,Megan Melch,Valerie A. Clausen,Pushkal Garg,Akshay K. Vaishnaw,Marianne T. Sweetser,Gabriel J. Robbie,John Vest

DOI: https://doi.org/10.1002/cpt.1974

2020-08-13

Abstract:Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid drug for the treatment of transthyretin (TTR)-mediated amyloidosis. This phase I, randomized, single-blind, placebo-controlled, single ascending dose study evaluated the pharmacodynamics, pharmacokinetics, and safety profile of subcutaneously administered vutrisiran (5-300 mg) in healthy subjects (n = 80). Vutrisiran treatment achieved potent and sustained TTR reduction in a dose-dependent manner, with mean maximum TTR reduction of 57-97%, maintained for ≥ 90 days post dose. Vutrisiran was rapidly absorbed (peak plasma concentration 3-5 hours post dose), had a short plasma half-life (4.2-7.5 hours), and plasma concentrations increased in a dose-proportional manner. Pharmacodynamic and pharmacokinetic results were similar in Japanese and non-Japanese subjects. Vutrisiran had an acceptable safety profile; the most common treatment-related adverse event was mild, transient injection site reactions in four (6.7%) vutrisiran-treated subjects. The favorable pharmacokinetic, pharmacodynamic, and safety results observed here support vutrisiran's continued clinical development.

pharmacology & pharmacy
Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review

Mohammad Amin Karimi,Fatemeh Esmaeilpour Moallem,Mohammad Sadra Gholami Chahkand,Eftekhar Azarm,Mohammad Javad Emami Kazemabad,Parisa Alsadat Dadkhah

DOI: https://doi.org/10.3389/fneur.2024.1465747

IF: 3.4

2024-09-02

Frontiers in Neurology

Abstract:Background Hereditary transthyretin (ATTRv) amyloidosis, a multifaceted disorder affecting multiple systems, substantially diminishes patients’ physical capabilities and overall quality of life. Patisiran and Vutrisiran, two Ribonucleic acid (RNA) interference therapies, target reducing both pathogenic and wild-type transthyretin (TTR) protein levels. This systematic review assesses the effectiveness and safety of these treatments in managing ATTRv. Methods A comprehensive, thorough literature search across databases including Embase, PubMed, Web of Science, Cochrane Central, and Google Scholar yielded 858 studies. Following removing duplicate and irrelevant articles, 676 distinct studies underwent review. These studies, conducted on a global scale, encompassed a range of methodologies, including clinical trials and indirect treatment comparisons. Results Ten studies, spanning a total population of 756 patients, were selected for in-depth analysis. Patisiran and Vutrisiran consistently demonstrated significant improvements in primary and secondary endpoints related to neuropathy, quality of life, and cardiac function. Both medications were well-tolerated, with primarily mild to moderate adverse events. Indirect treatment comparison studies indicated Vutrisiran’s superiority over Tafamidis in treating ATTRv amyloidosis. Conclusion This systematic review recommends using Patisiran and Vutrisiran to treat ATTRv amyloidosis. The findings suggest that these RNA interference therapies improve neuropathy, quality of life, and cardiac symptoms. The results indicate sustained benefits over prolonged treatment, with satisfactory safety profiles. However, potential biases, conflicts of interest in the studies, and limited follow-up periods in some trials necessitate cautious interpretation. Future research should address these limitations and provide more robust evidence for the long-term efficacy and safety of Patisiran and Vutrisiran in ATTRv treatment.

neurosciences,clinical neurology
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy

Violaine Planté-Bordeneuve,Valentine Perrain

DOI: https://doi.org/10.1080/17460441.2024.2306843

2024-01-29

Expert Opinion on Drug Discovery

Abstract:Introduction Hereditary transthyretin (ATTRv) amyloidosis is a progressive, fatal disorder caused by mutations in the transthyretin (TTR) gene leading to deposition of the misfolded protein in amyloid fibrils. The main phenotypes are peripheral neuropathy (PN) and cardiomyopathy (CM).

pharmacology & pharmacy
The Use Of Patisiran For The Improvement Of Cardiac Parameters In Hereditary Transthyretin-mediated Amyloidosis: A Systematic Review And Meta-analysis

Fred H.D. Charles,Tanesh Ayyalu,Sri Mandava,Ahmed K. Abdelrahman,Zainab Musleh,Luis Afonso

DOI: https://doi.org/10.1016/j.cardfail.2023.10.302

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease commonly affecting nerves and myocardium. RNA interference (RNAi) therapeutics for the long-term treatment of patients with hereditary transthyretin-mediated amyloidosis polyneuropathy are safe and effective. In this meta-analysis, we assess the hypothesis that Patisiran, an RNAi therapeutic agent, can also improve cardiac parameters in patients with transthyretin-mediated cardiomyopathy. Methods PubMed, Embase, Scopus, and Cochrane Library were searched for randomized controlled trials that evaluated cardiac parameters at baseline and post-RNAi therapy in patients with hereditary transthyretin-mediated amyloidosis cardiomyopathy. The keywords “RNA interference,” "Patisiran," “Amyloidosis,” and “Cardiomyopathy” were used. The PRISMA guidelines were used to search the databases. Studies were excluded if they did not assess or report the cardiac parameters. The change in means for LV mass, LV wall thickness, Left Ventricular Ejection Fraction percent (LVEF %), and Peak Global Longitudinal Strain percent were assessed. The Comprehensive Meta-analysis software (Version 3) was used for the statistical analysis. Results A total of 101 patients from 2 randomized controlled trials were included. Patisiran led to a change in means for LV mass of -15.40 ± 4.90 (SE) p-value 0.002. The mean for LV wall thickness (in mm) was decreased by -0.89 ± 0.38 (SE) p-value 0.02. The change in mean for Peak Global Longitudinal Strain was -0.35 ± 1.15 (SE) p-value 0.76, and the change in mean for LVEF% was 0.67 ± 0.68 (SE) p-value 0.32. The decrease in the mean LV mass and mean wall thickness were statistically significant, respectively, but changes in means for peak global longitudinal strain and LVEF% were insignificant. Conclusion Patisiran, an RNAi therapeutic agent, led to a statistically significant reduction in mean LV mass and wall thickness. Changes in means for peak global longitudinal strain were reduced, and LVEF% had mild improvement, but these results are not statistically significant. More studies are needed to evaluate a potentially impactful therapy in treating hereditary transthyretin-mediated amyloidosis cardiomyopathy.

cardiac & cardiovascular systems
Left Ventricular Deformation and Myocardial Work Parameters in Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran: A Single-Center Study

Daniela Di Lisi,Francesco Comparato,Antonella Ortello,Vincenzo Di Stefano,Filippo Brighina,Francesca Macaione,Giovanni La Fiura,Leandro Di Caccamo,Cristina Madaudo,Alfredo R Galassi,Giuseppina Novo

DOI: https://doi.org/10.3390/jcm13164914

2024-08-20

Abstract:Background: In recent years, many advances have been made in the treatment of hereditary transthyretin amyloidosis (ATTRv). Patisiran is a small-interfering RNA used to treat ATTRv with only polyneuropathy or polyneuropathy and cardiomyopathy. The aim of our study was to assess the effect of patisiran on cardiac function in ATTRv patients using speckle tracking echocardiography (STE) analysis. Methods: A single-center prospective study was performed enrolling 21 patients with ATTRv (11 M-52% of the population; 10 F-48% of the population; median age 66 ± 8.4 years old). A total of 7 patients had cardiac amyloidosis and polyneuropathy, and 14 patients had only polyneuropathy without cardiac involvement. Cardiological evaluation including electrocardiograms, echocardiography with STE, and assessment of myocardial work parameters was performed in all patients before starting patisiran and after 9-18 months. Functional capacity was assessed using the 6 min walk test; quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Results: We did not find a significant difference in gender prevalence of ATTR amyloidosis in all of the population (p-value 0.79), but we found that cardiac amyloidosis significantly predominated in the male sex compared to patients with only neuropathy. In all patients, we found a slight improvement in functional capacity and quality of life. We did not find significant changes in left ventricular ejection fraction (LVEF), but we found a significant improvement in left ventricular global longitudinal strain (GLS), global work waste (GWW), and global work efficiency (GWE), especially in patients with cardiac amyloidosis; E/e' average and left atrial stiffness also improved significantly in patients with cardiac amyloidosis. Conclusions: Our study confirms a positive effect of patisiran on cardiac function, particularly the absence of signs of subclinical deterioration as detected by very sensitive STE parameters such as GLS, MW, and atrial stiffness during follow up in patients treated with patisiran.
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

Mathew S Maurer,Parag Kale,Marianna Fontana,John L Berk,Martha Grogan,Finn Gustafsson,Rebecca R Hung,Robert L Gottlieb,Thibaud Damy,Alejandra González-Duarte,Nitasha Sarswat,Yoshiki Sekijima,Nobuhiro Tahara,Mark S Taylor,Milos Kubanek,Erwan Donal,Tomas Palecek,Kenichi Tsujita,W H Wilson Tang,Wen-Chung Yu,Laura Obici,Marcus Simões,Fábio Fernandes,Steen Hvitfeldt Poulsen,Igor Diemberger,Federico Perfetto,Scott D Solomon,Marcelo Di Carli,Prajakta Badri,Matthew T White,Jihong Chen,Elena Yureneva,Marianne T Sweetser,Patrick Y Jay,Pushkal P Garg,John Vest,Julian D Gillmore,APOLLO-B Trial Investigators

DOI: https://doi.org/10.1056/NEJMoa2300757

2023-10-26

Abstract:Background: Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. Methods: In this phase 3, double-blind, randomized trial, we assigned patients with hereditary, also known as variant, or wild-type ATTR cardiac amyloidosis, in a 1:1 ratio, to receive patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks for 12 months. A hierarchical procedure was used to test the primary and three secondary end points. The primary end point was the change from baseline in the distance covered on the 6-minute walk test at 12 months. The first secondary end point was the change from baseline to month 12 in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score (with higher scores indicating better health status). The second secondary end point was a composite of death from any cause, cardiovascular events, and change from baseline in the 6-minute walk test distance over 12 months. The third secondary end point was a composite of death from any cause, hospitalizations for any cause, and urgent heart failure visits over 12 months. Results: A total of 360 patients were randomly assigned to receive patisiran (181 patients) or placebo (179 patients). At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate of median difference, 14.69 m; 95% confidence interval [CI], 0.69 to 28.69; P = 0.02); the KCCQ-OS score increased in the patisiran group and declined in the placebo group (least-squares mean difference, 3.7 points; 95% CI, 0.2 to 7.2; P = 0.04). Significant benefits were not observed for the second secondary end point. Infusion-related reactions, arthralgia, and muscle spasms occurred more often among patients in the patisiran group than among those in the placebo group. Conclusions: In this trial, administration of patisiran over a period of 12 months resulted in preserved functional capacity in patients with ATTR cardiac amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO-B ClinicalTrials.gov number, NCT03997383.).
137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY

Simone Longhi(on Behalf Of),Mathew S Maurer,Marianna Fontana,John L Berk,Finn Gustafsson,Marcos Simões,Martha Grogan,Fábio Fernandes,Robert L Gottlieb,Milos Kubanek,Steen Poulsen,Thibaud Damy,Igor Diemberger,Nobuhiro Tahara,Wen-chuhg Yu,W H Wilson Tang,Laura Obici,Alejandra González-duarte,Yoshiki Sekijima,Matthew T White,Elena Yureneva,Patrick Y Jay,John Vest,Julian D Gillmore

DOI: https://doi.org/10.1093/eurheartjsupp/suac121.630

2022-12-14

European Heart Journal Supplements

Abstract:Abstract Background Transthyretin-mediated (ATTR) amyloidosis is a rapidly progressive, debilitating, and fatal disease caused by misfolded TTR accumulating in multiple organs and tissues. Patients with hereditary (hATTR) amyloidosis (also known as ATTRv amyloidosis) or wild-type (wtATTR) amyloidosis with cardiomyopathy exhibit decreased survival. Patisiran, an IV RNAi therapeutic that inhibits synthesis of wt and variant TTR, was approved for the treatment of hATTR amyloidosis with polyneuropathy. Exploratory analyses of a predefined cardiac subpopulation in the APOLLO study demonstrated the potential for patisiran to improve the manifestations of cardiomyopathy in patients with hATTR amyloidosis with polyneuropathy. Objective To investigate the safety and efficacy of patisiran in patients with ATTR amyloidosis with cardiomyopathy in the ongoing APOLLO-B study (NCT03997383). Material & Methods Patients were 18–85 years of age with evidence of cardiac amyloidosis by echocardiography (end-diastolic interventricular wall thickness >12 mm), and either ATTR amyloid deposition on tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with cardiomyopathy. Patients had a medical history of heart failure (HF) due to ATTR amyloidosis with at least 1 prior hospitalization for HF, or current clinical evidence of HF. Patients were randomized (1:1) to receive patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. After the double-blind, placebo-controlled period, all patients may receive patisiran in an open-label extension period for up to 36 months. The primary endpoint was change from baseline in 6-MWT at Month 12 with patisiran treatment, compared with placebo. Secondary endpoints evaluated the effect of patisiran vs placebo at Month 12 on QOL (KCCQ-OS score) as well as two sets of composite endpoints: 1) All-cause mortality, frequency of CV events (CV hospitalizations and urgent HF visits) and change from baseline in 6-MWT; and 2) All-cause mortality and frequency of all-cause hospitalizations and urgent HF visits. The pharmacodynamic effect of patisiran on serum TTR level (change from baseline through Month 12) was also assessed. Results & Discussion Enrollment completed (359 patients) in May 2021. About 80% of patients have wtATTR amyloidosis. Primary and secondary endpoint data will be presented, including change in 6-MWT and KCCQ-OS score at Month 12, in addition to safety data. Summary & Conclusion The primary results of the APOLLO-B study will inform the potential of patisiran as a treatment for the cardiomyopathy of ATTR amyloidosis. APOLLO-B will continue to investigate the efficacy and safety of patisiran on ATTR amyloidosis in an open-label extension period.

cardiac & cardiovascular systems
Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE

O Lairez,V Algalarrondo,T Damy,E Donal,S Bender,A Bakdache,P Y Jay,D Adams

DOI: https://doi.org/10.1093/eurheartj/ehae666.1039

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Introduction Transthyretin-mediated (ATTR) amyloidosis is a progressive, fatal disease in which the most serious manifestations are polyneuropathy and cardiomyopathy. Patients with hereditary ATTR (ATTRv; v for variant) amyloidosis commonly develop a mixed phenotype, and patients with wild-type ATTR amyloidosis predominantly have cardiomyopathy, although polyneuropathy may coexist. Patisiran, an RNAi therapeutic that rapidly knocks down TTR, has shown long-term benefit on measures of polyneuropathy in the APOLLO open-label extension (OLE) study in patients with ATTRv amyloidosis. Purpose To evaluate the long-term benefit of patisiran on survival, hospitalisations and cardiac parameters in a pooled cohort of patients with ATTR amyloidosis and evidence of cardiac involvement, across the patisiran clinical programme (Phase [Ph] 2 launched in 2012). Methods Post hoc analysis of pooled data from cardiac subpopulations of patients with ATTRv amyloidosis and polyneuropathy from 5-year Global OLE (Ph 2 OLE and Ph 3 APOLLO; patients with baseline left ventricular [LV] wall thickness ≥13 mm; absence of history of aortic valve disease or hypertension), and Ph 3 APOLLO-B (patients with wild-type or ATTRv cardiac amyloidosis). Patients received patisiran or placebo every 3 weeks for 18 months in APOLLO and 12 months in APOLLO-B; all patients received patisiran thereafter. Analyses included Kaplan-Meier estimates and Cox regression of survival and all-cause hospitalisations, and summary statistics of cardiac biomarkers and echocardiographic parameters by initial treatment arm. Results Pooled analysis included 496 patients (initial arm placebo, n=214; initial arm patisiran, n=282). Compared with placebo, patients initially receiving patisiran had better long-term survival and fewer hospitalisations (hazard ratio [95% confidence interval] over 84 months for all-cause mortality and all-cause hospitalisations: 0.59 [0.37–0.93] [Figure 1] and 0.77 [0.60–0.99], respectively). At baseline, NT-proBNP and troponin I levels, peak longitudinal strain and LV wall thickness were comparable between patisiran vs placebo-treated patients. Placebo-treated patients showed worsening of all these parameters whilst on placebo; the rates of worsening decreased once the patients initiated patisiran. In contrast, patients who initially received patisiran demonstrated relative stability over 84 months in the Global OLE and significant benefit compared with those initially treated with placebo. Conclusion Long-term benefit of patisiran in patients with cardiomyopathy was observed on survival, hospitalisations, cardiac biomarkers and echocardiographic parameters. Outcomes were significantly more favourable for those initially randomised to patisiran than placebo, highlighting the impact of initiating treatment early in the course of disease.

cardiac & cardiovascular systems
Efficacy and safety of patisiran for ATTRv-PN: a systematic review and meta-analysis

Xinyue Huang,Chong Sun,Haofeng Chen,Chongbo Zhao,Jie Lin

DOI: https://doi.org/10.1177/17562864241273079

2024-01-01

Therapeutic Advances in Neurological Disorders

Abstract:Background: Hereditary transthyretin amyloidosis (ATTRv; v for variant) with polyneuropathy is a rare, progressive, and fatal autosomal dominant disorder. Therapies such as liver transplantation and TTR stabilizations have limitations. Patisiran is a small interfering RNA (siRNA), offering potential as a genetic-level therapy for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). However, evidence on patisiran’s efficacy and safety for ATTRv-PN remains limited. Objectives: This study aimed to further clarify patisiran’s efficacy and safety for ATTRv-PN by meta-analysis. Design: Systematic review and meta-analysis. Methods: After literature searches in PubMed, Ovid MEDLINE, Embase, JBI EBP, Cochrane, and ClinicalTrials.gov databases on 7 June 2024, 11 studies with 503 patients were included and clinical data were extracted. Results: Results showed an 88% (95% confidence interval (CI): 81%–94%) pooled responsiveness rate. The standardized mean difference of modified Neuropathy Impairment Score plus 7 nerve tests (mNIS + 7) scores was −0.18 (95% CI: −0.32 to −0.03, p-value 0.018) and Norfolk Quality of Life–Diabetic Neuropathy was −0.21 (95% CI: −0.35 to −0.08, p-value 0.002). In total, 413 adverse events (AEs) (84.8%), 158 serious AEs (32.4%), and 37 deaths (7.6%) were recorded. Most of AEs were mild to moderate. No deaths were attributed to patisiran. However, there is no statistically significant improvement in Neuropathy Impairment Scores. Conclusion: In conclusion, patisiran was effective and safe for patients with ATTRv-PN. More large-scale clinical trials and long-term studies are necessary to further validate patisiran’s efficacy and safety. Trial registration: PROSPERO registration ID: CRD42023428838.

clinical neurology
RNA-targeting and gene editing therapies for transthyretin amyloidosis

Alberto Aimo,Vincenzo Castiglione,Claudio Rapezzi,Maria Franzini,Giorgia Panichella,Giuseppe Vergaro,Julian Gillmore,Marianna Fontana,Claudio Passino,Michele Emdin

DOI: https://doi.org/10.1038/s41569-022-00683-z

IF: 49.421

2022-03-23

Nature Reviews Cardiology

Abstract:Nature Reviews Cardiology, Published online: 23 March 2022; doi:10.1038/s41569-022-00683-zTransthyretin amyloidosis is a progressive, life-threatening disease caused by the accumulation of misfolded transthyretin, predominantly in the nerves and heart. In this Review, Aimo and colleagues provide an update on the treatment strategies aimed at blocking transthyretin production, including small interfering RNAs, antisense oligonucleotides and gene editing approaches.

cardiac & cardiovascular systems
Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran

Simoneide S Titze-de-Almeida,Pedro Renato de Paula Brandão,Ingrid Faber,Ricardo Titze-de-Almeida

DOI: https://doi.org/10.1007/s40291-019-00434-w

Abstract:In 2018, patisiran was the first-ever RNA interference (RNAi)-based drug approved by the US Food and Drug Administration. Now pharmacology textbooks may include a new drug class that results in the effect first described by Fire and Mello 2 decades ago: post-transcriptional gene silencing by a small-interfering RNA (siRNA). Patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) present with mutations in the transthyretin (TTR) gene that lead to the formation of amyloid deposits in peripheral nerves and heart. The disease may also affect the eye and central nervous system. The formulation of patisiran comprises the RNAi drug encapsulated into a nanoparticle especially developed to deliver the anti-TTR siRNA into the main TTR producer: the liver. Hepatic cells contain apolipoprotein E receptors that recognize ApoE proteins opsonized in the lipid carrier and internalize the drug by endocytosis. Lipid vesicles are disrupted in the cell cytoplasm, and siRNAs are free to trigger the RNAi-based TTR gene silencing. The silencing process involves the binding of siRNA guide strand to 3'-untranslated region sequence of both mutant and wild-type TTR messenger RNA, which culminates in the TTR mRNA cleavage by the RNA-induced silencing complex (RISC) as the first biochemical drug effect. Patisiran 0.3 mg/kg is administered intravenously every 3 weeks. Patients require premedication with anti-inflammatory drugs and antagonists of histamine H1 and H2 receptors to prevent infusion-related reactions and may require vitamin A supplementation. Following patisiran treatment, TTR knockdown remained stable for at least 2 years. Adverse effects were mild to moderate with unchanged hematological, renal, or hepatic parameters. No drug-related severe adverse effects occurred in a 24-month follow-up phase II open-label extension study. At the recommended dosage of patisiran, Cmax and AUC values (mean ± standard deviation) were 7.15 ± 2.14 μg/mL and 184 ± 159 μg·h/mL, respectively. The drug showed stability in circulation with > 95% encapsulated in lipid particles. Metabolization occurred by ribonuclease enzymes, with less than 1% excreted unchanged in the urine. Patisiran ameliorated neuropathy impairment according to the modified Neuropathy Impairment Score + 7 analysis of the phase III study. The Norfolk Quality of Life-Diabetic Neuropathy score and gait speed improved in 51% of the patisiran-treated group in 18 months. Additionally, the modified body mass index showed positive outcomes. Altogether, the data across phase I-III clinical trials points to patisiran as an effective and safe drug for the treatment of hATTR amyloidosis. It is hoped that real-world data from a larger number of patients treated with patisiran will confirm the effectiveness of this first-approved siRNA-based drug.
A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy

Gbolahan Olatunji,Emmanuel Kokori,Israel Charles Abraham,Oluwatobi Omoworare,Doyin Olatunji,Chimezirim Ezeano,Babawale Emmanuel Adeoba,Anthony Chidera Stanley,Awoyinfa Michael Oluwatobiloba,Omidiran Basit Oluwademilade,Kale Mekoya Shimelis,Olawale Olanisa,Nicholas Aderinto

DOI: https://doi.org/10.1097/md.0000000000038767

IF: 1.6

2024-06-28

Medicine

Abstract:Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.

medicine, general & internal
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Hartmut H Schmidt,Jonas Wixner,Violaine Planté-Bordeneuve,Francisco Muñoz-Beamud,Laura Lladó,Julian D Gillmore,Anna Mazzeo,Xingyu Li,Seth Arum,Patrick Y Jay,David Adams,Patisiran Post-LT Study Group,Christel Langestroer,Anna Huesing-Kabar,Matthias Schilling,Iyad Kabar,Rolf Backlund,Intissar Anan,Erik Nordh,Erika Uneus,Björn Pilebro,Ulrika Englund,Teresa Coelho,Marta Novais,Javier Perez,Ana Martins da Silva,Helena Pesseguerio Miranda,Joana Ramalho,Raquel Monte,Cristina Alves,Ines Cardaso,Nádia Guimaraes,Luca Gentile,Massimo Russo,Gianluca Di Bella,Amina Gaouar,Cécile Cauquil-Michon,Ilias Kounis,Andoni Echaniz-Laguna,Maëva Stéphant,Fetra Rakotondratafika,Yasmine Boubrit,Celine Labeyrie,Cecile Focsenaunu,Phillippe Le Corvoisier,Samar S Ayache,Thierry Gendre,Laetitia Vervoitte,Raphaele Arrouasse,Alvaro Gragera Martinez,Cristina Borrachero,Ana Manovel,Eusebio Diaz Rodriguez,Marta Gutiérrez Gándara,Elena Fabra Jiménez,Patricia Valentina Vélez Santamaría,Yurema Martínez Vilar,Alba Cachero,Lisa Rannigan,Marianna Fontana,Richard Orrell,Sarah Louth,Liza Chacko,Sindhu Varughese,Douglas Throburn,Oliver Cohen,Steven Law,Angelique Smit,Svetla Strehina

DOI: https://doi.org/10.1111/ajt.17009

Abstract:Hereditary transthyretin-mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long-standing treatment. However, disease progression continues post-LT. This Phase 3b, open-label trial evaluated efficacy and safety of patisiran in patients with ATTRv amyloidosis with polyneuropathy progression post-LT. Primary endpoint was median transthyretin (TTR) reduction from baseline. Twenty-three patients received patisiran for 12 months alongside immunosuppression regimens. Patisiran elicited a rapid, sustained TTR reduction (median reduction [Months 6 and 12 average], 91.0%; 95% CI: 86.1%-92.3%); improved neuropathy, quality of life, and autonomic symptoms from baseline to Month 12 (mean change [SEM], Neuropathy Impairment Score, -3.7 [2.7]; Norfolk Quality of Life-Diabetic Neuropathy questionnaire, -6.5 [4.9]; least-squares mean [SEM], Composite Autonomic Symptom Score-31, -5.0 [2.6]); and stabilized disability (Rasch-built Overall Disability Scale) and nutritional status (modified body mass index). Adverse events were mild or moderate; five patients experienced ≥1 serious adverse event. Most patients had normal liver function tests. One patient experienced transplant rejection consistent with inadequate immunosuppression, remained on patisiran, and completed the study. In conclusion, patisiran reduced serum TTR, was well tolerated, and improved or stabilized key disease impairment measures in patients with ATTRv amyloidosis with polyneuropathy progression post-LT (www.clinicaltrials.gov NCT03862807).
Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study

Taha N. Qarni,Felipe J. S. Jones,Brian Drachman,Sami Khella,Janice Pieretti,Nicolas Sarmiento Bustamante,Chafic Karam

DOI: https://doi.org/10.1186/s13023-024-03198-7

2024-05-11

Orphanet Journal of Rare Diseases

Abstract:There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficacy of combination therapy.

genetics & heredity,medicine, research & experimental
Patisiran for the treatment of patients with p.Ile88Leu hereditary transthyretin amyloidosis: an Italian real-life experience

Giacomo Urbinati,Ilaria Cani,Marco Currò Dossi,Simone Longhi,Samuela Carigi,Christian Gagliardi,Elena Biagini,Nazzareno Galiè,Pietro Cortelli,Pietro Guaraldi

DOI: https://doi.org/10.3389/fneur.2024.1415851

IF: 3.4

2024-06-08

Frontiers in Neurology

Abstract:Objectives: Evidence on the activity of patisiran therapy in specific subgroups of patients with hereditary transthyretin amyloidosis variant (ATTRv) is still scarce. This prospective real-world study was designed to provide the first in-depth clinical data on the effectiveness of patisiran in patients with ATTRv reporting the p.Ile88Leu variant, the most widespread variant in the Emilia-Romagna regional area, which has been less represented in previous clinical trials. Patients and methods: This prospective study evaluated all the patients with genetically proven ATTRv (p.Ile88Leu) and polyneuropathy treated with patisiran in the Emilia-Romagna referral centers for ATTRv (Institute of Neurological Sciences in Bologna and Division of Neurology in Rimini) from March 2021 to April 2023. All subjects underwent clinical and neurological evaluations at baseline and after 9–12 months of treatment. Results: A total of 22 patients were included in the study; the median age was 73 years (IQR: 9), the age at diagnosis was 72 years (IQR: 10), and the disease duration was 1.6 years (IQR: 2.3). We observed stability of all considered neurological and cardiological parameters at 9–12 months after the beginning of patisiran treatment. Conclusion: Our findings support the clinical data regarding the effectiveness of patisiran in stabilizing the disease course and extend this activity to the subset of patients with the p.Ile88Leu variant.

neurosciences,clinical neurology

Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy

Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis

Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review

Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy

The Use Of Patisiran For The Improvement Of Cardiac Parameters In Hereditary Transthyretin-mediated Amyloidosis: A Systematic Review And Meta-analysis

Left Ventricular Deformation and Myocardial Work Parameters in Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran: A Single-Center Study

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY

Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE

Efficacy and safety of patisiran for ATTRv-PN: a systematic review and meta-analysis

RNA-targeting and gene editing therapies for transthyretin amyloidosis

Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran

A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study

Patisiran for the treatment of patients with p.Ile88Leu hereditary transthyretin amyloidosis: an Italian real-life experience